GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Research & Development

Fortrea Holdings (FRA:K67) Research & Development : €0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Fortrea Holdings's Research & Development for the three months ended in Jun. 2024 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €0 Mil.

Fortrea Holdings Research & Development Historical Data

The historical data trend for Fortrea Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Research & Development Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Research & Development
- - - -

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fortrea Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortrea Holdings  (FRA:K67) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fortrea Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Research & Development
Comparable Companies
ZLAB MLTX DNLI BHVN MDGL NTLA ARWR RVMD IBRX DNA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
FTRE:USA FTRE1:Mexico
Address
8 Moore Drive, Durham, NC, USA, 27709
Website
https://www.fortrea.com
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings Headlines

No Headlines